alisporivir (Debio 025)
Debio 025 (alisporivir) is the first in a new class of drugs called cyclophilin inhibitors, with a potential in a wide range of therapeutic indications. Alisporivir was first thoroughly investigated for its antiviral properties in hepatitis C and HIV patients and consequently benefits from a large safety and efficacy database. Pre-clinical in vitro research from the Mondor Institute of Biomedical Research (INSERM U955) has shown evidence for the effectiveness of alisporivir against the replication of SARS-COV-2 (COVID-19). Alisporivir is currently tested in a phaseII study conducted in France by the AP-HP (Greater Paris University Hospitals) to assess the efficacy and safety of the compound.
January 18, 2021
Phase II Research Against Covid-19 Launched in France with Debiopharm’s Antiviral Alisporivir
September 8, 2015
Debiopharm International SA and Solid Biosciences, LLC, announce a collaboration to explore the use of Alisporivir (Debio 025) in muscular…
January 12, 2015
Debiopharm Group regains full rights to Alisporivir program
March 18, 2012
The cyclophilin inhibitor alisporivir prevents hepatitis C virus–mediated mitochondrial dysfunction
July 15, 2010
Debio-025 is more effective than prednisone in reducing muscular pathology in mdx mice
April 3, 2010
HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors.